Jun 9, 2005 - All patients were staged according to Ann Arbor clinical staging [8]. Five patients had stage I, 36 patients had stage II, 27 patients had stage III.
Annals of Oncology 16: 1524– 1529, 2005 doi:10.1093/annonc/mdi271 Published online 9 June 2005
Original article
Computed tomography and 18F-FDG positron emission tomography for therapy control of Hodgkin’s and nonHodgkin’s lymphoma patients: when do we really need FDG-PET? M. J. Reinhardt1,2*, C. Herkel2, C. Altehoefer3, J. Finke4 & E. Moser2 1
Department of Nuclear Medicine, University Hospital Bonn, Bonn; 2Department of Nuclear Medicine, University Hospital Freiburg, Freiburg; 3Department of Diagnostic Radiology, University Hospital Freiburg, Freiburg; 4Department of Hematology & Oncology, University Hospital Freiburg, Freiburg, Germany
Received 28 January 2005; revised 4 April 2005; accepted 13 April 2005
Background: The aim of this study was to evaluate the accuracy of computed tomography (CT) and [18F]fluoro-deoxy-D -glucose positron emission tomography (FDG-PET) for prediction of progression-free survival of Hodgkin’s disease (HD) and non-Hodgkin’s lymphoma (NHL) patients after completion of therapy. Patients and methods: CT and FDG-PET were performed in 40 HD, 17 indolent NHL and 44 aggressive NHL patients (29 women, 72 men; aged 41 ± 14 years) in a median of 2 months after therapy. Progression-free survival was evaluated using the Kaplan– Meier method. Independent prognostic factors were identified by means of Cox proportional hazards model. Results: CT imaging results were progressive disease (PD) in five, stable disease (SD) in 57, and partial response (PR) or complete remission (CR) in 39 patients. FDG-PET suggested residual lymphoma in 24 patients. Three-year progression-free survival rates after exclusion of five PD patients were: 100% (PET negative; CT: PR or CR), 81% (PET negative; CT: SD), 21% (PET positive; CT: SD) and 0% (PET positive; CT: PR). FDG-PET (P
